Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel Guzman-Perez

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Bioorganic & Medicinal Chemistry Letters|June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagementDaniel S La, Emily A Peterson, Christiane Bode, et al.
Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Journal of Medicinal Chemistry|March 22, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo ActivityRussell F Graceffa, Alessandro A Boezio, Jessica Able, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Bioorganic & Medicinal Chemistry Letters|June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagementDaniel S La, Emily A Peterson, Christiane Bode, et al.
Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Journal of Medicinal Chemistry|March 22, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo ActivityRussell F Graceffa, Alessandro A Boezio, Jessica Able, et al.
Pageof 5